FIBRINOGEN CONCENTRATES MARKET ANALYSIS

Regional Analysis

Global Fibrinogen Concentrates Market – Regional Insights

North America accounted for the largest market share in 2018, owing to launches of several national studies for the treatment of blood loss during cardiac surgeries in the region. For instance, in February 2017, the Peter Munk Cardiac Centre at Toronto General Hospital launched the FIBrinogen REplenishment in Surgery (FIBRES) study in acquired fibrinogen deficiency. The objective of the study is to compare the fibrinogen concentrate, Octafibrin, with a cryoprecipitate (a plasma-based frozen blood product) for the treatment of bleeding adult cardiac surgical patients with acquired hypofibrinogenemia.

Europe is also witnessing lucrative growth in the fibrinogen concentrates market owing to launches and approvals of new fibrinogen concentrates in the region. For instance, in June 2017, Octapharma AG received approval from the U.S Food and Drug Administration (FDA) for Fibryna, a human fibrinogen concentrate, developed for the treatment of acute bleeding incidences in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia. Furthermore, in November 2019, Octapharma AG received the European approval for label extension for fibryga for the treatment of acquired fibrinogen deficiency (AFD) in 15 European countries. The approval extends the market authorisation for fibryga for bleeding management in operative settings.